Arena Gets October FDA Deadline

Xconomy San Diego — 

Arena Pharmaceuticals (NASDAQ: ARNA), the San Diego-based developer of an obesity drug, said today that the FDA has set a deadline of October 22 for completing a review of Arena’s application to market lorcaserin in the U.S. The company’s application includes 18 clinical trials that enrolled more than 8,500 patients. If the FDA clears the drug for sale, it will be Arena’s first marketed product.

By posting a comment, you agree to our terms and conditions.

Comments are closed.